Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.
暂无分享,去创建一个
S. Solomon | M. Pfeffer | M. Sabatine | E. Braunwald | D. Morrow | T. O'donnell | T. Omland | J. Udell | P. Jarolim | Elaine B. Hoffman | A. Vora | S. Sloan | P. Jarolím | T. O'Donnell
[1] A. Go,et al. Fibroblast growth factor-23 and cardiovascular events in CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[2] D. Fliser,et al. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock , 2013, European heart journal. Acute cardiovascular care.
[3] Robert J. Vincent,et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. , 2013, American journal of physiology. Endocrinology and metabolism.
[4] E. Ingelsson,et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. , 2013, Kidney international.
[5] M. Pencina,et al. Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.
[6] B. Dai,et al. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model , 2012, PloS one.
[7] B. Kestenbaum,et al. Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-living Individuals Chs (cardiovascular Health Study) , 2022 .
[8] T. Szekeres,et al. Inorganic phosphate and FGF‐23 predict outcome in stable systolic heart failure , 2012, European journal of clinical investigation.
[9] S. Moe. Klotho: a master regulator of cardiovascular disease? , 2012, Circulation.
[10] L. Hsiao,et al. Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23 , 2012, Circulation.
[11] S. Solomon,et al. Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease , 2012, Circulation.
[12] D. Fliser,et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. , 2011, European heart journal.
[13] A. Go,et al. FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.
[14] G. Navis,et al. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[15] Jiang He,et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.
[16] Huiliang Xie,et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.
[17] E. Rimm,et al. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. , 2011, American heart journal.
[18] A. Hayen,et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.
[19] M. Wolf,et al. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease , 2010, Current opinion in nephrology and hypertension.
[20] L. Schurgers,et al. The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.
[21] T. Larsson. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[22] M. Shlipak,et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] M. Pfeffer,et al. A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.
[24] H. Melhus,et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. , 2009, Atherosclerosis.
[25] Thomas J. Wang,et al. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.
[26] M. Wolf,et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.
[27] S. Solomon,et al. Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease , 2007, Circulation.
[28] F. Kronenberg,et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. , 2007, Journal of the American Society of Nephrology : JASN.
[29] M. Pfeffer,et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.
[30] M. Pfeffer,et al. Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.
[31] K. Okawa,et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.
[32] S. Solomon,et al. Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial , 2006, Circulation.
[33] S. Solomon,et al. Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study , 2004, Circulation.
[34] M. Pfeffer,et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.
[35] H. Jüppner,et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. , 2003, Kidney international.
[36] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[37] K. White,et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.
[38] E. Nabel,et al. Angiotensin-converting enzyme 2--a new cardiac regulator. , 2002, The New England journal of medicine.
[39] Nancy R Cook,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.
[40] E. Uhlmann,et al. Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine. , 2001, Clinical Chemistry.
[41] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[42] M. Pfeffer,et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. , 1998, The American journal of cardiology.
[43] Tadashi Kaname,et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.
[44] R. Fandrich,et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. , 1995, The American journal of physiology.